

PTX-100 clinical data to be presented at international T-cell lymphoma meeting

MELBOURNE Australia, 21 March 2025: Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company developing personalised therapies for cancer, is pleased to announce that data arising from its Phase 1b study of PTX-100 in T-cell lymphomas (TCLs) will be presented in multiple sessions at the 16th Annual T-Cell Lymphoma Forum in La Jolla, California on 20-22 March.

The annual 16th T-Cell Lymphoma Forum is a specialist meeting to discuss the latest advances in the field of T-Cell lymphomas, and is attended by global key opinion leaders as well as industry participants. Prescient's data will be highlighted in a presentation by Professor H. Miles Prince, AM, a renowned lymphoma expert and Principal Investigator of the PTX-100 study, and new data on the pharmacokinetic characteristics of PTX-100 will be presented in a poster by Prescient's CMO Dr Terrence Chew.

As previously disclosed, the Phase 1b study of PTX-100 enrolled 19 TCL patients and demonstrated a good safety profile at doses of 500, 1,000 and 2,000 mg/m². To date, there has been a 42% overall response rate amongst all evaluable TCL patients, and 6 out of 7 evaluable CTCL patients received clinical benefit. Responders had a median progression-free survival (PFS) of over 10 months, surpassing the typical median PFS of approximately 3.1 months associated with standard care treatment vorinostat. The Phase 1 study has now closed with one patient still in complete response. This patient will continue to receive PTX-100 under compassionate access scheme in Australia.

The profile of Prescient's lead drug candidate, PTX-100 has been further characterised providing additional information on the mechanism of action, pharmacokinetics and drug interactions. In vitro drug interaction studies have shown PTX-100 to be a compound that has minimal risk of drug interaction with other compounds. The pharmacokinetics has shown that PTX-100 is readily cleared from the body and does not accumulate, demonstrating good safety when a patient is receiving the drug on a long term basis. Analysed data from the patients who had responded to treatment in the Phase 1 study has provided the rationale for proceeding to phase 2, which has been cleared by the FDA to begin.

Prescient Therapeutics CEO, James McDonnell, said, "This is a very timely meeting as we move to initiate our phase 2a study of PTX-100 in patients with relapsed and refractory cutaneous T-cell lymphomas (CTCL) next month. The forum is an excellent opportunity to engage global key opinion leaders in the field, including clinicians who will be conducting the study in their institutions. It will also be an excellent opportunity to consolidate relationships with potential partners for the further development of PTX-100."

To stay updated with the latest company news and announcements, [please update your details](#) on our investor centre.

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Targeted Therapy

PTX-100: is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 has recently completed a Phase 1b expansion cohort study in T cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T Cell Lymphomas. A Phase 2 study in Cutaneous T cell lymphoma (CTCL) is planned for initiation in April 2025.

Cell Therapy Platforms

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Find out more at www.ptxtherapeutics.com or connect with us via [LinkedIn](#).

The Board of Prescient Therapeutics Limited has approved the release of this announcement.



For more information please contact:

Company enquiries

James McDonnell

CEO

Prescient Therapeutics

james.mcdonnell@ptxtherapeutics.com

Investor enquiries

Christian Riedel

Reach Markets

1300 805 795

ir@reachmarkets.com.au

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website: [Supplemental COVID-19 Risk Factors](#)